Canadian Nuclear Laboratories : Canadian Nuclear Laboratories and TRIUMF to Host 11th Targeted-Alpha-Therapy Symposium
Canada's national nuclear laboratory and leading particle accelerator centre partner to host global forum on targeted radiopharmaceutical therapy
CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, and TRIUMF, one of the world's leading particle accelerator centres, jointly announced today that they are partnering to co-host the 11th Targeted-Alpha-Therapy Symposium (TAT11) to be held from April 1 - 5, 2019 at the Fairmont Château Laurier in Ottawa.
TAT11 is a global forum for academic and industry leaders to meet and discuss the latest technical, regulatory and clinical developments in targeted radiopharmaceutical therapy. The potential benefits of targeted-alpha-therapy in the battle against cancer and other diseases are significant. While existing radiation treatments target all cells in the vicinity of a tumor, both healthy and cancerous, targeted-alpha-therapy focuses the treatment application to cancerous or unhealthy cells. This limits the overall radiation dose a patient may receive, holds promise of better patient outcomes, and encourages a faster recovery time following treatment.
In addition to a variety of industry and academic speakers and presentations, the TAT11 conference will feature an exhibition for companies to showcase their products and services, and will include a tour of the Chalk River Laboratories.
"Targeted-alpha-therapy is one of the most promising areas of nuclear medicine, and could represent a leap forward in radiation therapy," commented Kathy McCarthy, Lab Director, CNL. "Given CNL's history as a world-leader in the development and delivery of medical isotope technology, hosting this important international conference alongside TRIUMF, a leader in subatomic physics, was a natural fit. We look forward to welcoming participants from around the globe to discuss this exciting medical technology."
As part of Atomic Energy of Canada Limited's (AECL) Federal Nuclear S&T Work Plan, CNL is conducting research to evaluate alpha therapy delivery methods. This includes the construction of a small alpha radioisotope generator to provide isotopes for CNL and its collaborators. CNL is also taking the necessary steps to grow and expand its resources and capabilities to pursue related research projects, including work alongside TRIUMF.
"Canada has an existing and powerful particle accelerator infrastructure capable of enabling a greater supply of targeted-alpha-therapy isotopes," explains Paul Schaffer, TRIUMF Associate Lab Director - Life Sciences Division. "It's very fitting to be hosting the next conference here and I am looking forward to both learning from others and advocating for what Canada can contribute to this exciting field.
"TRIUMF has established the feasibility of producing important targeted-alpha-therapy isotopes such as Ac - 225 using its 500 MeV cyclotron; and is also in the process of upgrading its infrastructure to improve safety and reliability of large-scale, accelerator-based isotope production," explains Schaffer.
"Both CNL and TRIUMF are committed to improving the health of Canadians through nuclear medicine, and TAT11 is an important medium to foster international partnerships and collaborations that are necessary to advance this therapy," added Corey McDaniel, Vice-President, Business Development with CNL. "It is our hope that this forum will build awareness around alpha therapy and spur further research to accelerate the development of these isotopes."
For more information on TAT11, including a detailed conference itinerary and exhibitor information, please visit www.tat11.com.
Canadian Nuclear Laboratories is a world leader in nuclear science and technology offering unique capabilities and solutions across a wide range of industries. Actively involved with industry-driven research and development in nuclear, transportation, clean technology, energy, defense, security and life sciences, we provide solutions to keep these sectors competitive internationally.
With ongoing investments in new facilities and a focused mandate, Canadian Nuclear Laboratories is well positioned for the future. A new performance standard reinforced with a strong safety culture underscores every activity.
Established in 1968 in Vancouver, TRIUMF is Canada's particle accelerator centre. The lab is a hub for discovery and innovation inspired by a half-century of ingenuity in answering nature's most challenging questions. Powered by its complement of top talent and accelerator infrastructure - including the world's largest cyclotron - TRIUMF is driving the leading edges of advanced isotope science, innovation, and technologies to address fundamental and applied problems in particle and nuclear physics, and the materials and life sciences. In collaboration with 20 Canadian universities, TRIUMF's diverse community of nearly 600 multidisciplinary researchers, engineers, technicians, tradespeople, staff, and students create a unique incubator for Canadian excellence, as well as a portal to premier global collaborations. At TRIUMF, we drive more than scientific discovery -- our passion for understanding everything from the nature of the nucleus to the cosmos creates into inspiration, improved health, economic opportunity, and a better world for all.
For more information see http://www.triumf.ca. Connect on Twitter, Facebook, and Instagram: TRIUMFlab
Director, Corporate Communications
Head, Strategic Communications
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Canadian Nuclear Laboratories via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Mandalay Resources går ut med måldatum för publicering av resultatet för det fjärde kvartalet och hela 2017 samt konferenssamtal19.2.2018 03:42 | Pressmeddelande
TORONTO, 16 februari 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" eller "Bolaget") (TSX:MND) meddelade idag att resultaten från det fjärde kvartalet och hela 2017 kommer att släppas efter att marknaden stängt den 21 februari 2018. Detta efterföljs av ett konferenssamtal för investerare och analytiker med Mandalays President och Chief Executive Officer, Mark Sander, den 22 februari 2018 klockan 08:00 (Toronto-tid). Analytiker och investerare inbjuds att delta med följande uppringningsnummer: Deltagarnummer: (201) 689-8341 Deltagarnummer (avgiftsfritt): (877) 407-8289 Konferens-ID: 13676606 En repris av konferenssamtalet kommer att finnas tillgänglig fram till den 8 mars 2018 klockan 23:59 (Toronto-tid), vilken man kommer åt med följande uppringningsnummer: Encore avgiftsfritt uppringningsnummer: (877) 660-6853 Encore-ID: 13676606 För mer information: Mark Sander President och Chief Executive Officer Greg DiTomaso Director of Investor Relations Kontakt: +1.647.260.
Standard Lithium Announces Closing of $21.6 million Bought Deal Private Placement of Units16.2.2018 19:25 | Pressmeddelande
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the "Units"), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters' (as defined below) option (the "Offering"). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share of the Company (a "Warrant Share") until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjus
Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers16.2.2018 14:00 | Pressmeddelande
Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of customer endpoints without added hardware or complexity. The Cisco endpoint security portfolio includes three industry-leading solutions-Cisco AMP for Endpoints, Cisco Umbrella, and Meraki Systems Manager to offer protection against advanced malware and threats. Security teams know the endpoints in their environments are being targeted by advanced threats, but often lack the security talent, tools, and budget to address those challenges. As a result, organizations of all sizes are choosing to augment their in-house IT security with managed security services. Nearly half of SMBs and enterprises in the US1 ar
Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family16.2.2018 14:00 | Pressmeddelande
Aurora Solar Technologies Inc. / Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora") ("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) is pleased to provide an update on the further development of its Decima Gemini(TM) infrared measurement technology for applications in the rapidly developing heterojunction (HJT) cell manufacturing market. HJT is an ultra high-efficiency solar cell design pioneered by Japan's Panasonic Corp., who is now also partnered with Tesla Inc. for solar products. According to Solar Media Ltd., HJT production capacity is expected to increase by 20 percent this year. To produce the electrical structure of a HJT cell, it is necessary to apply thin layers of amorphous silicon on both sides of a crystallin
Nasdaq Cited as a Leader in Governance, Risk, and Compliance Platforms by Independent Research Firm16.2.2018 13:35 | Pressmeddelande
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) was among the select companies that Forrester invited to participate in its 2018 Forrester Wave(TM) evaluation, Governance, Risk, And Compliance (GRC) Platforms, Q1 2018. In this evaluation, Nasdaq was cited as a Leader in Governance, Risk, and Compliance Platforms and received the maximum score of 5 for the evaluation criteria "Risk & Control Management", "Audit Management", "Dashboard and Reporting" and "Integration capabilities" for its BWise solutions. "We feel the strong scores we obtained in important functional areas provide assurance to our clients that they have selected a robust and future-proof software platform," said Tom Passon, Head of Product Innovation & Global Standards, Nasdaq BWise. "We are proud of this recognition that encourages us to further execute on our strategy to provide user-friendly, pre-configured best practice solutions that combine our innovative GRC software platform with leading expertis
Mandalay Resources Provides Target Release Date for Fourth Quarter and Full-Year 2017 Financial Results and Conference Call16.2.2018 13:30 | Pressmeddelande
TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX:MND) today announced that its fourth quarter and full-year 2017 financial results will be released after market close on February 21, 2018, followed by a conference call with Mark Sander, President and Chief Executive Officer of Mandalay, for investors and analysts on February 22, 2018 at 8:00 am (Toronto time). Analysts and interested investors are invited to participate using the following dial-in numbers: Participant Number: (201) 689-8341 Participant Number (Toll free): (877) 407-8289 Conference ID: 13676606 A replay of the conference call will be available until 11:59 pm (Toronto time), March 8, 2018 and can be accessed using the following dial-in number: Encore Toll Free Dial-in Number: (877) 660-6853 Encore ID: 13676606 For Further Information: Mark Sander President and Chief Executive Officer Greg DiTomaso Director of Investor Relations Contact: +1.647.260.1566 About Man
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum